Utilized in the treatment of adult patients with acute lymphoblastic leukemia.
Approved for the treatment of Philadelphia chromosome negative ALL.
Vincristine encapsulated in rigid lipid bilayer of sphingomyelin.
Encapsulated technology results in the leaking of active vincristine out of the liposome in a slow manner maintaining drug levels for a prolonged period of time.
Pharmacokinetic profile allows a continuous vincristine infusion and potentially results in greater activity in rapidly dividing cancer cells.
Dose intensity, dose density, and enhance target tissue delivery are achieved especially for tissues with a disrupted vasculature for those with a phagocytic system.
Doses of vincristine that are tolerable are 100% greater than conventionally administered vincristine.
Weekly dosing at 2.25 mg/m2.